Functional Genomics Takes Form
This article was originally published in Start Up
By 1994, functional genomics companies began forming to help a Big Pharma suddenly deluged by genomic data. Through the study of model genetic systems like nematodes and fruit flies, or homogenous peoples, these gene hunters hope to gain an understanding of how and when genes function--under normal conditions and in disease.
You may also be interested in...
Oxagen's goal is to use large familial clinical groups and sample banks to identify disease genes through agreements with three groups of academic clinical investigators, located throughout Europe.
PolyGenomics was spun-out of Yale University to develop a genetic amplification technology in the search for genes implicated in psychiatric illnesses.
GenoPlex Inc. hopes to provide validated gene targets to Big Pharma. The company is focusing its gene-seeking efforts on aging, learning and memory, and the action of anesthetics and alcohol.